Tech Company Financing Transactions
Vivace Therapeutics Funding Round
On 3/12/2025, Vivace Therapeutics received $35 million in Series D investment from RA Capital Management, Canaan Partners and Cenova Capital.
Transaction Overview
Company Name
Announced On
3/12/2025
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to support the continued clinical development of the its transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2929 Campus Dr. 150
San Mateo, CA 94403
USA
San Mateo, CA 94403
USA
Phone
Undisclosed
Website
Email Address
Overview
At Vivace Therapeutics, we pursue our work with passion, driven by a conviction to help people fight cancer and live life to the fullest.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sofie Qiao
Chief Scientific Officer
Leonard Post
VP - Bus. Development
Tuomas Holmberg
VP - Operations
Amy Pfeiffer
Browse more venture capital transactions:
Prev: 3/12/2025: sipMARGS venture capital transaction
Next: 3/12/2025: W3i Software venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs